|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Burnham Institute, La Jolla, CA; INSERM U428,
University of Paris V, Paris, France; CLB, Sanquin Blood Supply
Foundation, Amsterdam, The Netherlands; Utrecht Institute of
Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands;
Haemostasis, MRC Clinical Sciences Centre, ICMS, Hammersmith Hospital,
London, United Kingdom; and Electron Microscopy Center, Department of
Biology and Department of Biochemistry and Biophysics, Texas A&M
University, College Station, TX.
Despite recent studies, the organization of coagulation factor VIII
(FVIII) on a phospholipid (PL) membrane is not known in detail. Thus,
2-dimensional (2D) crystals of human FVIII lacking the B domain were
prepared for electron microscopy onto negatively charged PL monolayers.
The 3-dimensional (3D) density map of the PL-bound FVIII protein was
calculated at 1.5 nm. Existing atomic data and models for FVIII domains
were fitted unambiguously within the 3D density map of the molecule.
FVIII domains arrangement followed a compact spiral organization with
the A3 domains in close association with the C1 and C2 domains near the
PL surface. Viewed toward the membrane the A domains' heterotrimer is
oriented side-on with the pseudo-3-fold axis almost parallel to the PL surface and A1 fully covering C1. The C2 domain is partially overlapped by the A2 domain of an adjacent molecule in the 2D crystal, favoring close packing. Viewed parallel to the membrane, C2 is slightly inclined
to the PL surface covering an area of 12 nm2. Four C2 loops
are embedded within the lipid monolayer at about 0.7 to 1.0 nm depth.
C1 forms almost a right angle with C2, its long axis nearly parallel to
the membrane. The proposed structure for membrane-bound FVIII results
from modeling of the FVIII domains within a 3D density map obtained
from electron crystallography and accords with the main biochemical and
structural information known to date. A model is proposed for FVIIIa
and factor IXa assembly within the membrane-bound factor X-activating complex.
(Blood. 2002;99:1215-1223) Factor VIII (FVIII) is a plasma protein essential
for blood coagulation and is deficient or defective in individuals with hemophilia A. FVIII is synthesized as a 300-kd precursor protein with
domain structure A1-A2-B-A3-C1-C2.1,2 In plasma it
circulates as a series of noncovalently bound heterodimers, produced by
proteolytic cleavage at the B-A3 junction or within the B
domain.3 Thus, FVIII in vivo consists of a heavy chain
(HC) of variable molecular mass (from 90 kd, when only the A1-A2
domains are present, to 220 kd when the full-length B domain is
present) and a light chain (A3-C1-C2; LC) of 76 kd molecular mass (for
a review, see Lenting et al4).
In the process of blood coagulation, FVIII acts as a cofactor to the
serine protease factor IXa (FIXa). Before the initiation of
coagulation, FVIII circulates in a noncovalent complex with von
Willebrand factor (VWF). Limited proteolysis near the N-terminus of LC
by traces of thrombin removes a peptide containing a VWF-binding site,
resulting in release of free FVIII. Further proteolysis between the A1
and A2 domains results in generation of FVIIIa, the active
heterotrimeric cofactor. Binding of FVIIIa to negatively charged
phospholipid (PL) and to factor IXa (FIXa) form the factor X-ase
(FX-ase) complex. The product of the reaction, activated factor X
(FXa), forms with activated factor V (cofactor FVa) a similar
membrane-bound system, the prothrombinase complex that converts
prothrombin to thrombin.6 The serine proteases
FIXa and FXa are capable of cleaving their substrates without the
presence of protein cofactors. However, localizing the proteolytic
reaction onto negatively charged PL surface and locking the protein
conformation in complex with FVIIIa and FVa, respectively, amplifies
the reaction rates by up to 5 orders of magnitude.6
Malfunctioning at the level of FVIII causes a mild to severe bleeding
disorder called hemophilia A.7 Failure to form an active
FX-ase complex results in a dramatic reduction of FXa production, which
is required for the explosive formation of thrombin. There is therefore
great interest in elucidating the exact structure and conformation of
these proteins and the FX-ase complex.
To date, the structure of human FVIII and FV C2
domains9,10 and of porcine FIXa has been solved by x-ray
crystallography9 (although the membrane-binding Gla domain
of FIXa was poorly resolved). Attempts have been made to purify FVIII
in a quantity and form suitable for 3-dimensional (3D) crystallization;
however, the low plasma concentration (about 0.5 nM), its
heterogeneity, and sensitivity to proteolysis have made direct
crystallographic studies of the whole protein impossible thus far.
We have therefore used the method of 2-dimensional (2D) crystallization
onto coagulant-active PL monolayers followed by electron microscopy and
crystallography to solve the FVIII structure at 1.5 nm resolution in
its membrane-bound state.11-14 Within the 2D crystals,
FVIII was present as a noncovalently linked heterodimer of HCs (domains
A1-A2) and LCs (domains A3-C1-C2).14 Very little material
(of the order of micrograms) is needed to define a low-resolution 3D
density map of a protein organized in 2D crystals by electron crystallography. The crystallization/incubation times can be kept as
short as 3 hours allowing us to preserve the integrity of the protein
and the following steps must be achieved successfully: (1) generation
of good-quality 2D crystals, (2) estimation of the exact height of the
molecule above the membrane, and (3) collection of data from tilted 2D
crystals and generation of a 3D reconstruction, combining different projections.
By fitting and modeling of the atomic structures of the 5 major domains
(A1, A2, A3, C1, and C2)10,15,16 within the 3D envelope of
membrane-bound FVIII, it was possible to define their orientations
within the molecule and relative to the membrane surface. Further
biochemical information about the FIXa binding sites, the B domain and
activated protein C (APC) binding site positions within the FVIII
molecule were also taken into account during the modeling process. Data
for key point mutations,17 as well as for amino acid
residues potentially located at interdomain contact sites were also
considered. A model for the FVIII/FIXa complex was constructed based on
the crystal structure of FIXa,9 the membrane-bound FVIII
structure, and the FIXa/FVIIIa binding sites.
Electron microscopy
The samples were observed in a Phillips CM10 transmission electron
microscope operated at 100 kV. The 2D crystals were tilted from Data analysis
The 3D structure was calculated by merging to a common origin all of the 1083 structure factors or reflections, in reciprocal space. The IQ value of the included reflections was restricted to 7 and the sampling in the direction perpendicular to the 2D crystal plane set to zstar = 0.006. The overall average phase residual was 21.8°. Smooth curves were fitted manually along the lattice lines sampled at 1/20 (0.05) to obtain the correct amplitudes and phases for the 243 unique reflections. The final 3D map was calculated using the CCP4 crystallographic suite.22 The height of the FVIII was estimated from side-on views of liposome-attached molecules. The FVIII 3D structure was manually fitted within the `Ono 6.2.2' software package (TA Jones, Department of Molecular Biology, BMC, Uppsala University, Sweden, and M. Kjeldgaard, Department of Chemistry, Aarhus, University of Denmark). Fitting of individual FVIII domains within the 3D envelope The atomic coordinates of C2,10 the homology models for C1,16 and the 3 A domains15 were fitted within the 3D density of the membrane-bound FVIII using the `Ono' software package. This procedure was performed interactively, because the low symmetry, limited resolution, and tight packing of the FVIII molecules within the 2D crystals rendered automatic fitting ineffective.23The resultant atomic model for membrane-bound FVIII was geometrically optimized and refined in Insight II with the simulation program Discover (MSI, San Diego, CA). A3-C1 and C1-C2 domain interfaces were slightly modified to reduce steric clashes. Linker segments at A3-C1 and C1-C2 were built interactively using loop search protocols24 and secondary structure prediction25 followed by short energy refinement and 5 to 10 ps molecular dynamics (only the linker segments were allowed to move while the remaining structure was held fixed). Several structural models were imported back into `Ono' and superimposed over the 3D density map. The models best fitting the electron crystallography data were selected for further assessment and evaluated against known biochemical data. A preliminary model of the FVIII-FIXa-PL complex was assembled using Insight II. The x-ray structure of FIXa8 was docked onto the FVIII-PL model guided by experimental information including synthetic peptide studies and site-directed mutagenesis. The overall FVIII protein data bank file can be found on the following sites: http://europium.csc.mrc.ac.uk and http://klkemi.mas.lu.se/dahlback.
FVIII binding to liposomes Factor VIII was attached to liposomes and the height above the membrane estimated as described.12 Only a proportion of the liposomes was covered with protein; however, on Figure 1 it is easy to differentiate between naked and protein-coated liposomes. On larger liposomes, some FVIII molecules formed 2D arrays, also observed where the liposome surface was invaginated or curved. The above observations suggest a cooperative binding of the protein. From the edge-on view of 125 FVIII molecules picked from 9 different micrographs, the average height of the membrane-bound protein was 9.5 ± 0.5 nm.
3D density map of membrane-bound FVIII The overall 3D unit cell dimensions of membrane-bound FVIII were: a = 8.1 nm, b = 7.0 nm, c = 10 nm, and = 67°. The
symmetry of the plane group was P1.14 The 3D density
contours were displayed at a spacing of 0.7  , the lowest density
being 0.4 comparable to the previously published 2D contour
map14 (Figure 2).
Sigma values equal zero when the protein density signal is
comparable to the background noise of the electron micrograph. Because
the obtained FVIII 2D crystals were small (~1300 molecules) and
imperfectly ordered, a low signal-noise ratio and consequently low
sigma density contours were observed in the final 3D map.
Viewed toward the membrane plane (along the z-axis) the protein density corresponding to each molecule was well defined (Figure 2A). In the 2 orthogonal views (along the x- and y-axes), an overlapping head-to-tail arrangement between molecules was observed, FVIII being inclined 60° to 65° to the membrane plane, in both the X and Y directions (Figure 2B,C). The main protein mass was centered approximately 5 nm above the
membrane and was not well differentiated at contour levels below 1.8 The larger mass of the A domains, situated above the C domains and unconnected to the membrane surface, prevents close interactions between C domains of adjacent molecules. This results in the C2 domains being less well ordered than the A domains, giving a less pronounced density in the 3D map and also favoring tight packing in the main protein density, with significant gaps close to the phospholipid surface, when membrane-bound FVIII is organized in 2D crystals (Figure 2). Fitting of the FVIII domains with the 3D electron density map The existing model for the A domains,15 the atomic structure of C210 and the corresponding atomic model of C116 were oriented to match as closely as possible the 3D protein density distribution. The FVIII domain structures fitted the 3D map well when viewed toward the membrane (Figure 3A). However, part of A2 and a few loops from A3 and A1 deriving from the homology model15 were found outside the main contour when viewed parallel to the membrane (Figure 3B,C). We therefore continued manual fitting using the experimentally determined height of the molecule and the low-density areas (Figure 3) as guides. The placing of the A domain heterotrimer to align the A3 C-terminus to the C1 N-terminus oriented A2 in a position allowing most of the defined FIXa binding sites to be accessible to a macromolecular ligand.
Placement of the A domain model15 within the 3D map confirmed the previously suggested orientation of the heterotrimer.14 Viewed from the side, that is, along the x- and y-axes (Figure 3B,C), the A domains are oriented with the pseudo-3-fold axis forming an angle of approximately 15° with the membrane surface. The C domains were fitted manually within the electron density using the following additional information: (a) FVIII C2 has a cylindrical shape 4.5 nm by 3 nm10; (2) the fold of C domains is very well conserved,9,10 predicting C1 to have a very similar structure and shape to C2, as defined from homology modeling16,26; and (3) C1 and C2 were connected head-to-head as required by the positions of their C- and N-termini respectively.10,27 The C2 structure was fitted first, inclined at 60° toward the membrane surface (Figure 3B). The C2-PL contact area was estimated at 3 nm in diameter, and 4 of the loops from the lower part of the C2 domain insert approximately 0.7 nm into the lipid layer (Figure 3B,C). C1 was fitted between the A3 and C2 density with its long axis almost perpendicular to that of C2, such that the A3, C1, and C2 domains are associated in close proximity with each other and the PL surface. Viewed from the top C1 is largely covered by A3 and A1, whereas C2 lies outside the contour of the A domains (Figure 3A). Although the overall FVIII domain organization was consistent with many
available experimental data, we evaluated further our 3D structure by
considering also the interactions between adjacent FVIII molecules
within the membrane-bound 2D crystal (Figure
4). Four identical FVIII molecules were
fitted within the 3D map. The top view shows FVIII molecules arranged
in rows, tightly packed along the x-axis and a little further spaced
apart along the y-axis (Figure 4A). The C2 domains from one molecule are partially overlapped by the A2 and A3 domains of an FVIII molecule
from the adjacent row (Figure 4A,B). Viewed parallel to the membrane
(Figure 4B,C), FVIII molecules are tightly packed in the 2D crystal,
with C1 and C2 domains in close proximity to the A3 and A2 domains
of the next molecule in the same row (Figure 4B,C). Although some FVIII
loops protrude out of the main molecular contour, there were no clashes
between neighboring molecules or within one FVIII molecule. The tight
packing of the membrane-bound molecule into the 2D crystal allows only
one overall organization and orientation of the FVIII domains, when
fitted within the 3D map. No density within the 3D unit cell could be
ascribed to any extension of A2 into the B domain and the tight packing
did not leave any free volume or indication for a possible fitting of a
portion of B domain within the proposed 3D structure.
The best model structure for FVIII bound to the membrane obtained from
our analysis is presented in Figure 5. To
complete this model in detail, the N- and C-termini at the A3-C1
and C1-C2 boundaries were linked, optimizing the resultant orientation
of the domains within the 3D map and the known secondary structures including disulfide links.
For connection of the C1 and C2 domains, we built a relatively extended
and bent linker segment (Figure 6A)
taking into consideration 3 factors: (1) the positioning of
the C1 and C2 domains and their orientation relative to the membrane;
(2) the position of C1 residue Asp2170, following Cys2169, is
constrained in space due to the presence of the 2021-2069 disulfide
link; and (3) location of Ser2173 at the N-terminus of the C2 domain,
whose spatial position is well defined because it abuts the
Cys2174-Cys2326 disulfide link in the FVIII C2 crystal
structure.10 These constructions, based on the 3D map, led
to our proposal that only limited contacts are present between the 2 C
domains (Figure 6A).
Secondary structure prediction suggested that the C-terminal A3
residues (up to residue Tyr2017 approximately) would form a Interface of C2 domain with PL membrane The domain orientation described above should also be consistent with the positions of residues predicted or expected to be surface exposed in the FVIII structure; in particular those involved in PL binding. The depth of C2 insertion within the PL can only be determined with an accuracy reflecting the resolution along the z-axis in the 3D density map, which is slightly better than 2. However, fitting the x-ray structure of C2 within the low-resolution FVIII 3D envelope allows the membrane-binding loops to be unambiguously defined at atomic resolution. Four loops inserting into the membrane were characterized as the C2-membrane-binding area (Figure 6C,D). From left to right (Figure 6C) they are: loop 1 (2222-2227) containing Val2223; loop 2 (2196-2201) with Met2199 and Phe2200; loop3 (2313-2315) with Trp2313 and Val2314; and loop 4 (2249-2255) with Leu2251 and Leu2252 (3 of which contain 2 adjacent hydrophobic residues). Above loops 1 and 4 were situated 3 lysine residues (Lys2227, Lys2249, and Lys2258), which appeared close enough to the membrane surface for electrostatic interaction with negatively charged DOPS head groups. The C2-membrane binding area totalled 7 to 10 nm,2 or approximately 16 to 25 lipid molecules. Figure 6D is rotated 10° clockwise (viewed from above the membrane) to better illustrate the 4 membrane-binding loops and charged lysine residues. Loops 1, 2, and 4 correspond to the membrane-binding loops proposed from the x-ray structure.10Model of the FVIII/FIXa complex Although the active FX-ase complex is formed from PL, FIXa and proteolytically activated FVIIIa, the binding characteristics of FVIII and FVIIIa for FIXa and PL are similar28-30 and the FVIII/FIXa complex should share considerable structural similarity with that of FVIIIa/FIXa. Therefore, we built a model of the FVIII/FIXa complex to aid interpretation of FVIIIa/FIXa function at the molecular level, based on FVIII surface regions known to be implicated in FIXa binding,31 areas of FIXa known to play a role in FVIII interactions, and the overall orientations of the 2 molecules with regard to the membrane plane. Several key areas important for FVIIIa/FIXa interactions are appropriately distributed on each molecule (Figure 7), including (1) FIXa protease domain residues 301-303 and 333-33932,33 with FVIII A2 domain residues 558-56534 and 698-71235,36 and (2) the FIXa EGF1-EGF2 interface with FVIII A3 domain residues 1811-1818.37 Particularly good agreement was obtained between our model and that recently proposed for a region of the FVIIIa A2-FIXa protease domain interface.38 After positioning the cofactor and protease with appropriate membrane insertion of the FVIII C2 and FIXa Gla domains, the height of the FIXa active site corresponded to that reported by fluorescence measurements.39 In addition, the arrangement suggests availability of a face of the complex for potential docking of the substrate zymogen FX in the FX-ase complex, placing it in close proximity to the origin of the FVIII interdomain sequence a1 (approximately residues 337-372), which spans between A1 and A2. Although this highly acidic peptide cannot be modeled by homology, it has been implicated in FX interaction40 and our FVIII-FIXa model predicts it would lie in proximity to FX zymogen. The model also appears to allow the involvement of the FVIII C2 domain in FX interaction as suggested by recent studies.41
The purpose of this study was to define membrane-bound FVIII structure and conformation, fitting the available structural, biochemical, biophysical, and mutation information within an experimentally derived 3D envelope of the molecule. Solving the structure of FVIII will improve our understanding of its structure-function relationship in both health and disease. The FVIII 3D density map revealed the main protein density distribution within the 2D crystals (Figure 2). Direct visualization of secondary structures is not possible at 1.5 to 2.0 nm resolution; however, for a 170-kd molecule, a 3D structure solved at 1.5 nm provides excellent guidance for the correct arrangement of all 5 FVIII domains in membrane-bound conformation. Because data were collected from small, negatively stained 2D crystals, some areas within the molecule may be less well resolved than others due to preferential staining of charged and hydrophilic surfaces and low signal-noise ratio of the 3D map. However, the 3D structure of the complete FVIII 2D crystal (Figure 2) provided a unique template for the organization of membrane-bound FVIII molecules in conditions close to those found in vivo. The 4-step manual fitting of the domain structures to the density map was performed iteratively: (1) matching the main 3D map with the main protein density derived from the A and C domains; (2) checking domain interfaces to optimize the orientation; (3) verifying that no clashes occurred between adjacent molecules within the 2D crystal; and (4) considering the resultant model with respect to published biochemical and structural data such as hemophilic mutations, surface-exposed residues, and binding sites for other proteins, enabling us to produce a reliable 5-domain structure for PL-bound FVIII (Figure 5). The highest protein density area within the 3D map (Figure 2, red contour) was well defined and located unambiguously the predominant mass of the FVIII molecule, the A domain heterotrimer (~130 kd). The C domains (each ~ 20 kd) were oriented with careful attention to placements of domain interfaces. C1 orientation was constrained by the shortness of the A3-C1 linker and the C1 intradomain disulfide bridge. The A3-C1 angle could be varied only slightly without affecting the quality of fitting to the electron density. For example, rotation of the C1 domain along its long axis displaced its N-terminus away from the A3 C-terminus (Figure 5). C1 orientation further determines the length and orientation of the C1-C2 link (Figure 6A) suggesting that a "vertical"orientation of C1 on top of C2 for FVIII, as proposed for both FVIIIa and FVa42,43 may be unlikely. The experimentally determined height and dimensions of membrane-bound FVIII impose that C1 is sandwiched between the A domains and C2, assuming a rather horizontal orientation in respect to the membrane plane (Figures 5 and 6). It is possible that FVa assumes a membrane-bound conformation allowing the C domains to form a cylinder out of the main contour of the A domains.12,14 Without direct structural data, however, even at low resolution, comparison of our experimentally based FVIII model with FVa models is difficult, and further structural data on the C1-C2 domain pair will be needed to define the organization of the FVa domains. The tight packing of the 5 FVIII domains within the 3D unit cell (Figure 2) resulted in a compact "spiral" organization of the FVIII domains within the unit cell volume (8 × 7 × 10 nm), with the A3, C1, and C2 domains in close association near the PL membrane. As described previously,14 no electron density could be assigned for extension of the A2 domain into the B domain. Because the purified human FVIII used here bore the expected heterogeneous heavy chains indicating the presence of variable lengths of B domain following the acidic a2 sequence, this tight domain packing suggests either that only FVIII molecules with no B domain extension are capable of forming regular arrays on the surface, or that fragments of the highly glycosylated and hydrophilic B domain extend past and above the A domain heterotrimer into solvent, poorly structured and therefore not resolved in the 3D density map. No density, however, corresponding to the B domain mass (up to 100 kd) could be seen in the side-on view of FVIII attached to liposomes. Increased confidence in this A3-C1-C2 organization and orientation derives from the fact that the whole structure is in agreement with the overall dimensions of membrane-bound FVIII and places particular FVIII features in accordance with known biochemical and mutational data as given below. First, the 5 glycosylated asparagine residues (Asn41 and Asn239 in A1, Asn582 in A2, Asn1810 in A3, Asn2118 in C1)44,45 are surface exposed in the FVIII structure (Figure 5). Second, FIXa binding sites on FVIII (511-530, 558-565 and 707-712 in A2, and 1811-1818 in A3), determined by synthetic peptide studies,34-37 are surface exposed on one face of A2 at the appropriate height to interact with the FIXa protease domain (sequences 130-132 and 172-171)38 and epidermal growth factor-like domains (Figure 7). In addition, mutation at Arg527 (Figure 7) reduced apparent FIXa binding affinity.46 Recently, a further A2 sequence (482-493) was suggested to be a FIXa recognition site47,48; however, we have been unable to modify the FVIII-FIXa proposed model to include this region, in agreement with another recent report.38 This apparent discrepancy may indicate more than one productive conformation of FVIII bound to FIXa; alternatively, the domain arrangements of FVIII and FVIIIa may differ slightly in exposure of FIXa-binding regions as suggested for the 558-565 sequence.49 Third, APC cleavage sites at Arg336 and Arg562 (for a review, see Lenting et al4) are fully surface exposed (Figure 5). Residue Arg562 is also referred as being part of a FIXa binding site and is correctly positioned within our FVIII-FIXa model for this role (Figure 7). Fourth, there are 3 acidic peptides (a1, a2, and a3) at the interdomain interfaces (A1-A2, A2-B, and B-A3), each bearing proteolytic cleavage sites and containing sulfated tyrosine residues, important for protein-protein interactions such as A1-A2 interdomain contacts or membrane-assembled FVIII binding to factor X (a1),40 association with thrombin prior to FVIII activation (a2) or VWF (a3) (for a review, see Lenting et al4). These peptides cannot be modeled by homology (being absent in ceruloplasmin) and our structure resolution is insufficient to define their orientation; however, they can be accommodated as exposed structures accessible for protein-protein interaction and proteolytic degradation. Fifth, we considered interactions of the C domains. There are 2 notable solvent-exposed clusters of hydrophobic residues on the flank of C1 opposite to the A domains, including residues Ile2080, Leu2171, Ile2145, and Leu2107 in the first patch and residues Leu2123, Val2125, Met2124, Ile2102, Phe2068, and Phe2127 in the second (not shown). Such clusters frequently form part of protein recognition sites. The first cluster is close to Arg2116, Ser2119, and Tyr2105; mutation of these 3 residues results in hemophilia A and may be involved directly or indirectly in the binding of VWF.26,50 The second cluster may also be directly involved with VWF binding, because it is located close to Arg2150 (Figure 5), a residue closely associated with VWF interaction.51-53 Our structural model is in accord with these clinical data and structure-function studies. The C2 domain possesses functionally important binding sites, which may be evaluated in our model. These involve interaction with other proteins such as VWF, factor Xa, and thrombin as well as PL membranes (for a review, see Pratt54). Binding site(s) on C2 for PL and VWF are either identical or closely adjacent55,56 and direct binding of the isolated C2 domain to both VWF and negatively charged PL membranes has been demonstrated.55,57 The C-terminal 2303-2332 sequence was suggested to form an interactive site for both VWF and PL58 and this peptide has been shown to inhibit binding of FVIII and isolated C2 domain to both VWF and PL. Although the sequence 2303-2324 was shown by nuclear magnetic resonance studies to form an amphipathic helix, which bound to synthetic PL vesicles,59 resolution of the C2 structure by x-ray crystallography10 demonstrated that 2303-2332 forms a part of the domain core, requiring major rearrangement to expose the sequence as a helix. This suggests that the 2303-2332 peptide, in solution, mimics in a nonspecific way the binding characteristics of the complete domain, although recent studies support the concept of conformational changes within the C2 domain on membrane binding or FVIIIa/FIXa complex formation.60,61 The C2 crystal structure suggested explicitly a different molecular mechanism for PL binding involving insertion of hydrophobic side chains from 3 C2 loops while several positively charged side chains made contact with negatively charged PL head groups. Although none of these 3 hydrophobic loops or basic residues are contained within the sequence 2303-2332, several are within the sequence 2181-2243, which is also involved in PL binding,62 and alanine scanning mutagenesis recently demonstrated involvement of Met2199, Phe2200, Leu2251, and Leu2252 in forming a PL-binding site on C2.63,64 In our FVIII-PL model we position these 3 hydrophobic loops at the C2-PL interface, together with a fourth loop bearing Trp2313, Val2314, and His2315, and a similar grouping of basic residues (Figure 6). This fourth loop is within the 2303-2332 sequence closely associated with PL binding in previous studies; Figure 5 shows that the termini of the 2303-2332 sequence are exposed distal to the membrane while the mid portion, bearing the hydrophobic residues 2313-2315, is buried within the PL bilayer. Similar arguments as to the nature of the protein-lipid interface have resulted from solution of the structure of the homologous factor V C2 domain,9 and mutational analysis65,66 supporting a general model of FV/FVIII-PL binding. There is considerable evidence for closely related or even identical binding sites on the C2 domain for VWF and PL with the 2303-2332 sequence implicated, and the substitution Arg2307Gln is found in a patient with mild hemophilia A with a defect in VWF binding.26 However, for VWF there is also strong evidence that the N-terminal acidic region of the A3 domain (the a3 sequence) contains a key binding site67-69; although this sequence cannot be modeled by homology, we can place the termini speculatively in the region of the A2-A3 interface (residues 716 and 1692, Figure 5). C1 domain residues Ile2098, Ser2119, and Arg2150 have also been implicated in VWF interaction,50-53 and a recombinant C1-C2 molecule bound to immobilized VWF at least 2 orders of magnitude better than isolated C2,70 confirming a role for both C domains in addition to the a3 sequence. Figure 5 shows that in our FVIII-PL model the hypothetical a3 region and residues on the C domains associated with VWF binding are found surface exposed and spread in a patch across the membrane-proximal region of the FVIII molecule. We propose that binding of the FVIII molecule via a3, C1, and C2 to the carrier VWF multimer interferes grossly with binding of FVIII to a membrane via the C2 domain, until released by cleavage at Arg1689 removing the a3 peptide. This novel FVIII domain arrangement, with the A3 domain and a3 peptide position close to the membrane and compactly associated with the C domains, shares one feature (the membrane-proximal orientation of A3 in the A domain heterotrimer) with that predicted in a recent modeling study of membrane-bound FVa,65 although an alternative arrangement for modeling FVa with the A2 domain closest to C2-PL has also been proposed.71 In the present FVIII-PL study, however, the domain geometry is based directly on the experimental 3D density map and extensive biochemical data, supporting the presented domain arrangement. C2 has also been reported to interact with FXa and thrombin, both of which selectively cleave and activate FVIII. Binding of intact FVIII light chain and of the isolated C2 domain to FXa (inactivated at the active site) could be competed with the C2-derived synthetic peptide 2253-2270.41 This peptide binding was also shown to be specific for FXa as against FVIII binding to VWF, PL, FIXa, or FX, and inhibited FXa-dependent FVIII activation.72 Residues in the 2253-2270 sequence are exposed in our model, forming well-distinguished solvent-exposed clusters near the membrane binding loop containing Ile2251 and Ile2252 and in proximity to the C1-C2 binding interface. Interaction of C2 with active site-inhibited thrombin has also been described, and isolated C2 domain inhibited thrombin activation cleavage of FVIII at the N-terminus of the A3 domain (Arg1689).73 This site has not yet been localized; however, it appears distinct from the FXa-binding site.72 The major goals of this study were first to define the domain arrangements of FVIII bound to PL, and second to propose a docking structure for the FVIII/FIXa complex, which could stand as a model for the tenase complex of activated FVIII with FIXa on a PL surface. To build and evaluate the tenase model, we mapped proposed FVIIIa/FIXa binding sites as well as functionally significant point mutations. The model satisfies the various criteria described above and we suggest that it may prove useful in discussion of the structural and functional aspects of the tenase complex. Refinement of the present FVIII-FIXa model structure using both modeling and further experimental studies is in progress and should shed light on a clinically and structurally important macromolecular system.
This work was accomplished in the School of Biochemistry and Molecular Biology, University of Leeds. S.S.-M. would like to thank Dorit Hanein (The Burnham Institute) for her support and Jo Jaeger and Simon Phillips from the Astbury Centre of Structural Biology (The University of Leeds) for their support and use of the computer.
Submitted June 28, 2001; accepted October 4, 2001.
Supported by a 3-year research grant from the Wellcome Trust (United Kingdom) (S.S.-M. and A.H.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Svetla Stoilova McPhie, Wadsworth Center, NY State Department of Health, Empire State Plaza, PO Box 509, Albany, NY 12201-0509; e-mail: svetla{at}burnham.org.
1. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330-337[CrossRef][Medline] [Order article via Infotrieve]. 2. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature. 1084;312:342-347[CrossRef][Medline] [Order article via Infotrieve]. 3. Fay PJ, Anderson MT, Chavin SI, et al. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochem Biophys Acta. 1986;871:268-278[CrossRef][Medline] [Order article via Infotrieve].
4.
Lenting P, van Mourik JA, Mertens K.
The life cycle of coagulation factor VIII in view of its structure and function.
Blood.
1998;92:3983-3996
5.
Kane WH, Davie EW.
Blood coagulation factors V and VIII: structure and functional similarities and their relationship to hemorrhagic and thrombotic disorders.
Blood.
1988;71:539-555
6.
van Dieijen G, Tans G, Rosing J, Hemker HC.
The role of phospholipid and factor VIIIa in the activation of bovine factor X.
J Biol Chem.
1981;256:3433-3442 7. Kazazian HH, Tuddenham EGD, Antonarakis SE. Haemophilia A and parahemophilia: deficiencies of coagulation factors VIII and V. In: Scriver CR,Beaudet AL,Sly WS,Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 1995:3241-3267.
8.
Brandstetter H, Bauer M, Huber R, Lollar P, Bode W.
X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B.
Proc Natl Acad Sci U S A.
1995;92:9796-9800 9. Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature. 1999;402:434-439[CrossRef][Medline] [Order article via Infotrieve]. 10. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human FVIII at 1.5 Å resolution. Nature. 1999;402:439-442[CrossRef][Medline] [Order article via Infotrieve]. 11. Brisson A, Olofsson A, Ringler P, Schmutz M, Stoylova S. Two-dimensional crystallization of proteins on planar lipid films and structure determination by electron crystallography. Biol Cell. 1994;80:221-229[CrossRef][Medline] [Order article via Infotrieve]. 12. Stoylova S, Mann K, Brisson A. Structure of membrane-bound human factor Va. FEBS Lett. 1994;351:330-334[CrossRef][Medline] [Order article via Infotrieve]. 13. Stoylova S, Gray E, Barrowcliffe TW, Kemball-Cook G, Holzenburg A. Structure determination of lipid-bound human blood coagulation factor IX. Biochem Biophys Acta. 1998;1383:175-178[CrossRef][Medline] [Order article via Infotrieve].
14.
Stoylova SS, Lenting PJ, Kemball-Cook G, Holzenburg A.
A electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers.
J Biol Chem.
1999;274:36573-36578
15.
Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G.
A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.
Blood.
1997;89:2413-2421 16. Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RCR. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis. 2000;30:268-279[CrossRef][Medline] [Order article via Infotrieve].
17.
Kemball-Cook G, Tuddenham EGD, Wacey AI.
The factor VIII structure and mutation resource site: HAMSTeRS version 4.
Nucleic Acid Res.
1998;26:216-219 18. MacDonald RC, MacDonald RI, Menco BPM, Takeshita K, Subbarao NK, Hu LR. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochimica et Biophysica Acta. 1991;1061:297-303[Medline] [Order article via Infotrieve]. 19. Holzenburg A, Bewley MC, Wilson FH, Nicholson WV, Ford RC. Three-dimensional structure of photosystem II. Nature. 1993;363:470-472[CrossRef]. 20. Amos LA, Henderson R, Unwin PNT. Three-dimensional structure determination by electron microscopy of two-dimensional crystals. Prog Biophys Mol Biol. 1982;39:183-231[Medline] [Order article via Infotrieve]. 21. Yeager M, Unger VM, Mitra AK. Three-dimensional structure of membrane proteins determined by two-dimensional crystallization, electron cryomicroscopy and image analysis. Methods Enzymol. 1999;294:135-180[Medline] [Order article via Infotrieve]. 22. Collaborative Computational Project No.4. Acta Crystallogr D Biol Crystallogr. 1994;50:760-763[CrossRef][Medline] [Order article via Infotrieve]. 23. Volkmann N, Hanein D. Quantitative fitting of atomic models into observed densities derived by electron microscopy. J Structural Biol. 1999;125:176-184[CrossRef][Medline] [Order article via Infotrieve]. 24. Shenkin PS, Yarmush DL, Fine RM, Wang H, Levinthal C. Predicting antibody hypervariable loop conformation, I: ensembles of random conformations for ring like structures. Biopolymers. 1987;26:2053[CrossRef][Medline] [Order article via Infotrieve]. 25. Rost B, Sander C. Prediction of protein secondary structure at better than 70% accuracy. J Mol Biol. 1993;232:584-559[CrossRef][Medline] [Order article via Infotrieve].
26.
Liu M-L, Shen BW, Nakaya S, et al.
Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstroms human C2-domain crystal structure.
Blood.
2000;96:979-987 27. Villoutreix BO, Bucher P, Hofmann K, Baumgartner S, Dahlback B. Molecular models for the two discoidin domains of human blood coagulation factor V. J Mol Model. 1998;4:268-275[CrossRef].
28.
Duffy EJ, Parker ET, Mutucumarana VP, Johnson AE, Lollar P.
Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles.
J Biol Chem.
1992;267:17006-17011
29.
Lenting PJ, Donath MJSH, Van Mourik JA, Mertens K.
Identification of a binding site for blood coagulation factor IX on the light chain of human factor VIII.
J Biol Chem.
1994;269:7150-7155
30.
Saenko EL, Scandella D, Yakhyaev AV, Greco NJ.
Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and platelets.
J Biol Chem.
1998;273:27918-27926 31. Mertens K, Celie PHN, Kolkman JA, Lenting PJ. Factor VIII-factor IX interactions: molecular sites involved in enzyme-cofactor complex assembly. Thromb Haemost. 1999;82:209-217[Medline] [Order article via Infotrieve].
32.
Mathur A, Bajaj SP.
Protease and EGF1 domains of factor IXa play distinct roles in binding of factor VIIIa.
J Biol Chem.
1999;274:18477-18486 33. Kolkman JA, Lenting PJ, Mertens K. Region 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are FVIII-interactive sites involved in stimulation of enzyme activity. Biochem J. 1999;339:18477-18486.
34.
Fay PJ, Beattie T, Huggins CF, Regan LM.
Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site.
J Biol Chem.
1994;269:20522-20527 35. Liles DK, Monroe DM, Roberts HR. The factor VIII peptide consisting of amino acids 698 to 712 enhances factor IXa cleavage of factor X. Blood. 1997;90(suppl.1):463a. 36. Jorquera JI, McClintock RA, Roberts JR, MacDonald MJ, Houghten RA, Fulcher CA. Synthetic peptides derived from residues 698 to 710 of factor VIII inhibit factor IXa activity. Circulation. 1992;86:685a.
37.
Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K.
The sequence Gln1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.
J Biol Chem.
1996;271:1935-1940
38.
Bajaj SP, Schmidt AE, Mathur A, et al.
Factor IXa:factor VIIIa interaction: helix 330-338 of factor IXa interacts with residues 558-565 of the A2 subunit of factor VIIIa.
J Biol Chem.
2001;276:16302-16309
39.
Mutucumarana VP, Duffy EJ, Lollar P, Johnson AE.
The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa.
J Biol Chem.
1992;267:17102-17121 40. Lapan KA, Fay PJ. Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost. 1998;80:418-422[Medline] [Order article via Infotrieve].
41.
Nogami l, Shima M, Hozokawa K, et al.
Role of factor VIII C2 domain in factor VIII binding to factor Xa.
J Biol Chem.
1999;274:31000-31007 42. Pellequer J-L, Gale AJ, Griffin JH, Getzoff ED. Homology models of the C domains of blood coagulation factors V and VIII: a proposed membrane binding model for FV and FVIII C2 domains. Vol 15. Blood Cells: Mol Dis.; 1998:448-461. 43. Gale A, Pellequer J-L, Getzoff ED, Griffin JH. Structural basis for hemophilia A caused by mutations in the C domains of blood coagulation factor VIII. Thromb Haemost. 2000;83:78-85[Medline] [Order article via Infotrieve]. 44. Sandberg H, Brandt DJ, Alin P. Glycosylation pattern of a B-domain-deleted factor VIII molecule (r-VIII-SQ). Thromb Haemost. 1995;73:1214. 45. Medzihradszky KF, Besman MJ, Burlingame AL. Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry. Anal Chem. 1997;69:3986-3994[Medline] [Order article via Infotrieve]. 46. Celie PHN, Van Stempvoort G, Jorieux S, Mazurier C, van Mourik JA, Mertens K. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol. 1999;106:792-800[CrossRef][Medline] [Order article via Infotrieve].
47.
Fay PJ, Scandella D.
Human inhibitor antibodies for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa.
J Biol Chem.
1999;274:29826-29830
48.
Koszelak ME, Huggins CF, Fay PJ.
Sites in the A2 subunit involved in the interfactor VIIIa interaction.
J Biol Chem.
2000;275:27137-27144
49.
Fay PJ, Mastri M, Koszelak ME, Wakabayashi H.
Cleavage of FVIII heavy chain is required for the functional interaction of A2 subunit with FIXa.
J Biol Chem.
2001;276:12434-12439
50.
Jacquemin M, Lavend'homme R, Benhida A, et al.
A novel cause of mild/moderate hemophilia A: mutation scattered in the factor VIII C1 domain reduce the factor VIII binding to von Willebrand factor.
Blood.
2000;96:958-965
51.
Peerlinck K, Jacquemin MG, Amout J, et al.
Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patient with mild hemophilia A.
Blood.
1999;93:2267-2273 52. Gilles JG, Lavend'homme L, Peerlinck K, et al. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb Haemost. 1999;82:40-45[Medline] [Order article via Infotrieve].
53.
Jacquemin M, Benhida A, Peerlinck K, et al.
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.
Blood.
2000;95:156-163 54. Pratt KP. Relating structure to function: the role of the C2 domain in factor VIII. Curr Opin Drug Discovery Dev. 2000;3:516-526[Medline] [Order article via Infotrieve].
55.
Saenko EL, Shima M, Rajalakashmi KJ, Scandella D.
A role for the C2 domain of factor VIII binding to von Willebrand factor.
J Biol Chem.
1994;269:11601-11605
56.
Saenko EL, Scandella D.
A mechanism for inhibition of factor VIII binding to phospholipids by von Willebrand factor.
J Biol Chem.
1995;270:13826-13833 57. Takeshima K, Fujikawa T. The phospholipid binding properties of the C2 domain of human factor VIII. Thromb Haemost. 1999;82(suppl):234[Medline] [Order article via Infotrieve].
58.
Foster PA, Fulcher CA, Houghten RA, Zimmerman TS.
Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of FVIII inhibit FVIII binding to phosphatidyl serine.
Blood.
1990;75:1999-2004 59. Gilbert GE, Baleja JD. Membrane-binding peptide from the C2 domain of factor VIII forms an amphiphatic structure as determined by NMR spectroscopy. Biochemistry. 1995;34:3022-3031[CrossRef][Medline] [Order article via Infotrieve]. 60. Saenko E, Sarafanov A, Greco N, et al. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions: application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine containing membranes. J Chromatogr A. 1999;852:59-71[CrossRef][Medline] [Order article via Infotrieve]. 61. Cullinan DB, Philip B, Arena AA, Baleja JD, Gilbert GE. Factor VIII C2 domain binds von Willebrand factor and phospholipid with high affinity and exhibits conformational flexibility. Blood. 2000;96:636a.
62.
Healey JF, Barrow RT, Tamim HM, et al.
Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.
Blood.
1998;92:3701-3709 63. Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe S. Four hydrophobic amino acids of the factor VIII C2 domain contribute to the membrane-binding motif. Blood. 2000;96:633a.
64.
Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JMR, Lollar P.
Antigenicity of putative phospholipid membrane-binding residues in factor VIII.
Blood.
2001;97:169-174 65. Nicolaes GA, Villoutreix BO, Dahlback B. Mutation in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex. Blood Coagul Fibrinolysis. 2000;11:89-100[Medline] [Order article via Infotrieve]. 66. Kim SW, Quinn-Allen MA, Camp JT, et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry. 2000;39:1951-1958[CrossRef][Medline] [Order article via Infotrieve].
67.
Leyte A, van Schijndel HB, Niehrs C, et al.
Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor.
JBiol Chem.
1991;266:740-746
68.
Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ.
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.
Blood.
1995;85:3150-3157
69.
Saenko EL, Scandella D.
The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor.
J Biol Chem.
1997;272:18007-18014 70. Liu ML, Thompson AR. Factor VIII's C1 domain enhances C2 binding of factors IX/IXa, X/Xa and von Willebrand factor (vWf). Blood. 2000;96:489a. 71. Pellequer J-L, Gale AJ, Getzoff ED, Griffin JH. Three-dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost. 2000;84:849-857[Medline] [Order article via Infotrieve]. 72. Nishiya K, Shima M, Nogami K. Anticoagulant effect of a synthetic peptide containing residues Thr2253-Gln2270 within factor VIII C2 domain which selectively inhibits factor Xa-catalyzed factor VIII activation. Blood. 2000;96:632a.
73.
Nogami K, Shima M, Hosokawa K, et al.
Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689.
J Biol Chem.
2000;275:25774-25780
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  H. Meems, A. B. Meijer, D. B. Cullinan, K. Mertens, and G. E. Gilbert Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity Blood, October 29, 2009; 114(18): 3938 - 3946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Soeda, K. Nogami, K. Nishiya, M. Takeyama, K. Ogiwara, Y. Sakata, A. Yoshioka, and M. Shima The Factor VIIIa C2 Domain (Residues 2228-2240) Interacts with the Factor IXa Gla Domain in the Factor Xase Complex J. Biol. Chem., February 6, 2009; 284(6): 3379 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vencesla, M. A. Corral-Rodriguez, M. Baena, M. Cornet, M. Domenech, M. Baiget, P. Fuentes-Prior, and E. F. Tizzano Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites Blood, April 1, 2008; 111(7): 3468 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Shen, P. C. Spiegel, C.-H. Chang, J.-W. Huh, J.-S. Lee, J. Kim, Y.-H. Kim, and B. L. Stoddard The tertiary structure and domain organization of coagulation factor VIII Blood, February 1, 2008; 111(3): 1240 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-C. Hsu, K. P. Pratt, and A. R. Thompson The factor VIII C1 domain contributes to platelet binding Blood, January 1, 2008; 111(1): 200 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Rossetti, C. P. Radic, M. Candela, R. P. Bianco, M. de Tezanos Pinto, A. Goodeve, I. B. Larripa, and C. D. De Brasi Sixteen novel hemophilia A causative mutations in the first Argentinian series of severe molecular defects Haematologica, June 1, 2007; 92(6): 842 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dahlback and B. O. Villoutreix Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure-Function Relationships and Molecular Recognition Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1311 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Purohit, K. Ramani, R. Sarkar, H. H. Kazazian Jr., and S. V. Balasubramanian Lower Inhibitor Development in Hemophilia A Mice following Administration of Recombinant Factor VIII-O-Phospho-L-serine Complex J. Biol. Chem., May 6, 2005; 280(18): 17593 - 17600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yegneswaran, R. M. Mesters, J. A. Fernandez, and J. H. Griffin Prothrombin Residues 473-487 Contribute to Factor Va Binding in the Prothrombinase Complex J. Biol. Chem., November 19, 2004; 279(47): 49019 - 49025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Autin, W. H. Lee, M. A. Miteva, K. Mertens, K. P. Radtke, and B. O. Villoutreix Molecular Models of the Procoagulant Intrinsic Tenase Complex. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1723 - 1723. [Abstract]
|
|
|
|
|
|
D. W. Scott and N. M. Ananyeva Mutagenesis lowers factor VIII immunogenicity Blood, August 1, 2004; 104(3): 598 - 599. [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Adams, M. F. Hockin, K. G. Mann, and S. J. Everse The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function PNAS, June 15, 2004; 101(24): 8918 - 8923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wakabayashi, J. Freas, Q. Zhou, and P. J. Fay Residues 110-126 in the A1 Domain of Factor VIII Contain a Ca2+ Binding Site Required for Cofactor Activity J. Biol. Chem., March 26, 2004; 279(13): 12677 - 12684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. d'Oiron, J.-M. Lavergne, R. Lavend'homme, A. Benhida, J.-C. Bordet, C. Negrier, K. Peerlinck, J. Vermylen, J.-M. Saint-Remy, and M. Jacquemin Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development Blood, January 1, 2004; 103(1): 155 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Manithody, P. J. Fay, and A. R. Rezaie Exosite-dependent regulation of factor VIIIa by activated protein C Blood, June 15, 2003; 101(12): 4802 - 4807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bovenschen, R. C. Boertjes, G. van Stempvoort, J. Voorberg, P. J. Lenting, A. B. Meijer, and K. Mertens Low Density Lipoprotein Receptor-related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII J. Biol. Chem., March 7, 2003; 278(11): 9370 - 9377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. M. Persson, B. O. Villoutreix, A.-M. Thamlitz, K. E. Knobe, and J. Stenflo The N-terminal Epidermal Growth Factor-like Domain of Coagulation Factor IX. PROBING ITS FUNCTIONS IN THE ACTIVATION OF FACTOR IX AND FACTOR X WITH A MONOCLONAL ANTIBODY J. Biol. Chem., September 13, 2002; 277(38): 35616 - 35624. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
60°
to +60° in a rotational holder,
) chains of the 5 FVIII domains are presented as
worms: A1 domain residues colored in red, A2 in yellow, A3 in green, C1
in magenta, and C2 in cyan. Domains were fitted within the 3D density
corresponding to one membrane-bound molecule contoured at 0.4
strands are shown as flattened
ribbons. A1 domain (residues 1-336) is in red with magenta 
